Reprogramming M2 macrophages via TLR7/8 agonist-loaded hollow MnO2 nanovehicles to suppress the progression of liver cancer
PLOS One · 2026
DOI: 10.1371/journal.pone.0358567 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Pei-Pei He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China. Hauptthemen laut MEDLINE: Oxides, Manganese Compounds, Imidazoles, Nanoparticles. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nanchong City School Science and Technology Strategic Cooperation Project, Research and Development Program of North Sichuan Medical College, Guang’an Science and Technology Bureau.
Abstract (Originalsprache)
As a prevalent malignancy, liver cancer ranks as the third most common cause of cancer mortality globally. Within the tumor microenvironment, tumor-associated macrophages (TAMs) exhibit contrasting functional phenotypes: the anti-tumor M1 type and the pro-tumor M2 type. Reprogramming TAMs from the M2 to the M1 phenotype has emerged as a promising immunotherapeutic strategy. Here, we engineered a multi-nano therapeutic system, PAH@HMMDN@R848, by loading a TLR7/8 agonist (R848) onto hollow MnO 2 nanoparticles (HMMDN) and coating with polyallylamine hydrochloride (PAH). In vitro, this system efficiently repolarized M2 macrophages to the M1 phenotype, evidenced by decreased CD206, Arg-1, IL-10 and increased CD80, iNOS, TNF-α (P < 0.05). Under acidic/glutathione-rich conditions, HMMDN degraded to release Mn 2+ , which served as a T 1 -weighted MRI contrast agent with a high relaxivity (r 1 = 5.255 mM - 1 s - 1 ). Mechanistically, PAH@HMMDN@R848 activated both NF-κB (via R848) and STING (via Mn 2+ ) pathways, leading to synergistic M1 polarization. In a subcutaneous H22 liver cancer mouse model, intratumoral injection of PAH@HMMDN@R848 significantly suppressed tumor growth (tumor inhibition rate 80.6%) without obvious systemic toxicity. Immunohistochemistry and cytokine analysis revealed that the treatment increased M1 macrophage infiltration (CD80 + ) and reduced M2 macrophages (CD206 + ) within tumors, along with elevated TNF-α/iNOS and decreased IL-10/Arg-1. This study presents a multifunctional nanoplatform capable of TAMs reprogramming and MRI diagnosis, offering a promising approach for liver cancer theranostics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
- Innovation Centre for Science and Technology of North Sichuan Medical College, Nanchong, Sichuan, China.
- Biotechnology Innovation Drug Application and Transformation Key Laboratory of Sichuan Province, North Sichuan Medical College, Nanchong, Sichuan Province, China.
- Department of Ultrasound, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
ORCID-Profile: Pei-Pei He
Förderung
- Nanchong City School Science and Technology Strategic Cooperation Project
- Research and Development Program of North Sichuan Medical College
- Guang’an Science and Technology Bureau
Zitieren
APA
He, P. P., Hou, Z. J., Li, H. M., Zhang, J. X., Chen, A. Q., Miao, Q. Y., Yang, C. F., Yu, J. H., & Li, Y. (2026). Reprogramming M2 macrophages via TLR7/8 agonist-loaded hollow MnO2 nanovehicles to suppress the progression of liver cancer. PLOS One. https://doi.org/10.1371/journal.pone.0358567
Vancouver
He PP, Hou ZJ, Li HM, Zhang JX, Chen AQ, Miao QY, et al. Reprogramming M2 macrophages via TLR7/8 agonist-loaded hollow MnO2 nanovehicles to suppress the progression of liver cancer. PLOS One. 2026. doi:10.1371/journal.pone.0358567
BibTeX
@article{He2026,
author = {He, Pei-Pei and Hou, Zheng-Ju and Li, Han-Mei and Zhang, Ji-Xuan and Chen, An-Qi and Miao, Quan-You and Yang, Chao-Feng and Yu, Jin-Hong and Li, Yang},
title = {Reprogramming M2 macrophages via TLR7/8 agonist-loaded hollow MnO2 nanovehicles to suppress the progression of liver cancer},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0358567}
}
EUVIMED